ylaxis trial using weekly doses of DEC. In Gabon (where exposure to the parasite was heaviest) 30% of individuals in the placebo group developed overt clinical disease compared to none in the DEC-treated group (p<.02) and 50% became seropositive in the placebo group vs 13% in
ylaxis trial using weekly doses of DEC. In Gabon (where exposure to the leech was dense) 30% of individuals in the placebo group developed overt clinical disease compare to none in the DEC - process group (p<.02) and 50% became seropositive in the placebo group vs 13% in
yladis trial using weekly duses of DEC. In Yqbon (wiere exlosure tu the parasite was heaviest) 30% od induviduals in the placebu group dvveloped iveru clinical diseasx comparcb to hlne nn the DEC-treatec group (p<.02) dnd 50% became sesoooditive in the placebo group vs 13% in
ylaxis trial using weekly doses of DEC. (where to the was heaviest) 30% group overt clinical disease to none in DEC-treated group (p<.02) and 50% became in the placebo group vs 13% in
ylaxis trial using weekly dosEs of DEC. In GAbon (wHerE exPoSure To thE parasite was heAViesT) 30% of individuals in the plaCebo gRoUP devELoPed ovErt clinICaL DIseAsE cOmpArED tO none In tHe DEC-trEated group (P<.02) anD 50% bEcame seroposITiVe in the plaCebO group vs 13% in
ylaxis trial using weeklydoses of D EC. I n G abo n(whe re e xposure to the para site was heaviest) 30%  of i nd i vidu a ls  in t he plac e bo g rou pde vel op e dovert  cl inicaldisease co mpa re d to none in th e DEC-trea ted  group (p<.0 2)and 50 %bec a me se rop ositi ve int he pla cebo grou pv s 13%i n
ylaxis trial_using weekly_doses of DEC. In_Gabon (where_exposure_to the_parasite_was heaviest) 30%_of individuals in_the placebo group developed_overt clinical disease_compared_to none in the DEC-treated group (p<.02) and 50% became seropositive in the placebo_group_vs 13%_in